Safety and clinical efficacy outcomes from the Long-term extension study of tolebrutinib in patients with relapsing multiple sclerosis: 2-year results

被引：0
|
作者：
Oh, J. [1 ]
Syed, S. [2 ]
Orogun, L. [2 ]
Xu, Z. [3 ]
Turner, T. J. [2 ]
Fox, R. J. [4 ]
机构：
[1] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada
[2] Sanofi, Cambridge, MA USA
[3] Sanofi, Bridgewater, MA USA
[4] Cleveland Clin, Mellen Ctr Multiple Sclerosis, Cleveland, OH USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P308
引用
收藏
页码：342 / 343
页数：2
相关论文
共 50 条
  • [31] LONG-TERM EFFICACY OF OFATUMUMAB IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS
    Hauser, Stephen
    Fox, Edward
    Aungst, Angela
    Su, Wendy
    Zielman, Ronald
    Das Gupta, Ayan
    Stoneman, Dee
    Robertson, Derrick
    Cohen, Jeffrey
    Kappos, Ludwig
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (09):
  • [32] Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis
    Montalban, Xavier
    Comi, Giancarlo
    Antel, Jack
    O'Connor, Paul
    de Vera, Ana
    Cremer, Malika
    Sfikas, Nikolaos
    von Rosenstiel, Philipp
    Kappos, Ludwig
    JOURNAL OF NEUROLOGY, 2015, 262 (12) : 2627 - 2634
  • [33] Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis
    Xavier Montalban
    Giancarlo Comi
    Jack Antel
    Paul O’Connor
    Ana de Vera
    Malika Cremer
    Nikolaos Sfikas
    Philipp von Rosenstiel
    Ludwig Kappos
    Journal of Neurology, 2015, 262 : 2627 - 2634
  • [34] Long-term efficacy and safety of ponesimod: results from randomized phase ii core and extension studies in relapsing-remitting multiple sclerosis
    Freedman, M.
    Pozzilli, C.
    Havrdova, E. Kubala
    Coyle, P.
    Lemle, A.
    Burcklen, M.
    Larbalestier, A.
    Hennessy, B.
    Scherz, T.
    Vaclavkova, A.
    Olsson, T.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 222 - 222
  • [35] Long-term effects of cladribine tablets treatment on cognition, relapses, MRI, and safety outcomes in patients with relapsing multiple sclerosis: 4-year results from the CLARIFY-MS Extension study
    Selmaj, Krzysztof
    Langdon, Dawn
    Brochet, Bruno
    Solari, Alessandra
    Havrdova, Eva Kubala
    Patti, Francesco
    Piehl, Fredrik
    Smyk, Andrzej
    Lehn, Annette
    Nolting, Axel
    Montalban, Xavier
    Lechner-Scott, Jeannette
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 655 - 657
  • [36] Long-term safety and efficacy of delayed-release dimethyl fumarate in paediatric patients with relapsing-remitting multiple sclerosis: a long-term extension of the FOCUS study
    Alroughani, R.
    Huppke, P.
    Pultz, J.
    Parks, B.
    Beynon, V.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 147 - 148
  • [37] Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension
    Santos, Raul D.
    Duell, P. Barton
    East, Cara
    Guyton, John R.
    Moriarty, Patrick M.
    Chin, Wai
    Mittleman, Robert S.
    EUROPEAN HEART JOURNAL, 2015, 36 (09) : 566 - 575
  • [38] Long-term safety and efficacy of natalizumab and assessment of 2-year freedom from clinical disease activity in patients with multiple sclerosis in the TYSABRI(R) observational programme
    Pellegrini, F.
    Belachew, S.
    Butzkueven, H.
    Kappos, L.
    Trojano, M.
    Wiendl, H.
    Zhang, A.
    Arnold, R.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 220 - 221
  • [39] Long-term safety and efficacy of risperidone in children with disruptive behaviour disordersResults of a 2-year extension study
    Magali Reyes
    Roza Olah
    Krisztina Csaba
    Ilse Augustyns
    Marielle Eerdekens
    European Child & Adolescent Psychiatry, 2006, 15 : 97 - 104
  • [40] EFFICACY AND SAFETY OF LONG-TERM TREATMENT WITH LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: RESULTS OF A 2-YEAR, OPEN-LABEL EXTENSION STUDY
    Correll, C.
    Goldman, R.
    Tocco, M.
    Pikalov, A.
    Deng, L.
    Loebel, A.
    Coghill, D.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2019, 53 : 105 - 105
12345